Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers-Reply

JAMA Oncol. 2020 Dec 1;6(12):1983. doi: 10.1001/jamaoncol.2020.4824.

Authors

Adam J Schoenfeld¹, Helena A Yu¹

Affiliation

¹ Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.

PMID: 33119042
DOI: 10.1001/jamaoncol.2020.4824

No abstract available

Publication types

Letter
Comment

MeSH terms

Acrylamides
Aniline Compounds
Bevacizumab
ErbB Receptors / genetics
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Progression-Free Survival

Substances

Acrylamides
Aniline Compounds
Bevacizumab
osimertinib
EGFR protein, human
ErbB Receptors